ArticleBMC public health2026
Informing life-course immunization and pandemic preparedness: a COVID-19 vaccine evaluation and HPV introduction experience in Sierra Leone.
Article in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From Product Availability to Population Protection: Vaccine Deployment Readiness in Sierra Leone.Annals of global health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundSierra Leone launched its COVID-19 vaccination in March 2021 and achieved 73.2% full coverage among individuals aged 12 and older by December 2022. In October 2022, the country introduced the human papillomavirus (HPV) vaccine for 10-year-old girls, leveraging infrastructure and lessons from the COVID-19 vaccine deployment. We conducted a COVID-19 vaccine post-introduction evaluation (cPIE) to document best practices, assess impact on routine immunization, and identify key levers that supported HPV vaccine rollout, and recommendations for future pandemic preparedness.
methodsWe adapted the World Health Organization COVID-19 Post-Introduction Evaluation tool and conducted 84 structured interviews with national, district, and health facility staff in six districts, complemented by a desk review. Qualitative data were analysed thematically.
resultsBy October 2023, COVID-19 full vaccination coverage was estimated at 86.7% among people aged ≥ 12 years, and first-dose coverage exceeded 100% based on programme denominators, likely reflecting uncertainty in population projections. Over 84% of doses were administered via surge campaigns and periodic intensification of routine immunization. Key lessons included: (1) delivering adult vaccination services closer to clients (e.g., schools, workplace, and homes); (2) re-tooling existing health infrastructure and systems; (3) engaging community leaders to build demand across the life-course; (4) strengthening electronic data systems for vaccination tracking; (5) integrating vaccines within one delivery platform; and (6) promoting operational innovations for rapid response. HPV vaccine uptake exceeded expectations, with 119% of the targeted girls vaccinated and 68% of doses administered in schools, supported by COVID-19 vaccination platforms, including cold chain, digital registries, and community mobilization networks. However, surge delivery approaches strained workforce capacity and were reported to disrupt routine immunization in some areas.
conclusionSierra Leone's experience highlights the feasibility of using emergency vaccination platforms to accelerate life-course vaccination and new vaccine introductions in low-resource settings. Sustained preparedness will require earlier integration guidance, strengthened coordination, financing, and improved data systems to support adult and adolescent immunization alongside routine services.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.